Dr. Kumar on the Future Directions With Pirtobrutinib in MCL


In Partnership With:

Anita Kumar, MD, discusses future directions with pirtobrutinib in mantle cell lymphoma.

Anita Kumar, MD, medical oncologist, Regional Care Network Medical Site Director, MSK Basking Ridge, Memorial Sloan Kettering Cancer Center, discusses future directions with pirtobrutinib (LOXO-305) in mantle cell lymphoma (MCL).

Pirtobrutinib is a BTK inhibitor that has shown activity in patients with MCL, including those who previously received standard BTK inhibitors, Kumar says. Moreover, pirtobrutinib appears to be well tolerated and could offer patients a convenient, once-daily dosing option, Kumar explains.

Additional studies evaluating pirtobrutinib are planned, such as a phase 3 study comparing pirtobrutinib with investigator’s choice of ibrutinib (Imbruvica), acalabrutinib (Calquence), or zanubrutinib (Brukinsa), Kumar continues. Further research is needed to inform whether pirtobrutinib can be combined with other agents, such as venetoclax (Venclexta) to enhance the efficacy observed with the BTK inhibitor alone, Kumar concludes.

Clinicians referring a patient to MSK can do so by visiting msk.org/refer, emailing referapatient@mskcc.org, or by calling 833-315-2722.
Related Videos
Mike Lattanzi, MD, medical oncologist, Texas Oncology
Vikram M. Narayan, MD, assistant professor, Department of Urology, Emory University School of Medicine, Winship Cancer Institute; director, Urologic Oncology, Grady Memorial Hospital
Stephen V. Liu, MD
S. Vincent Rajkumar, MD
Pashtoon Murtaza Kasi, MD, MS
Naseema Gangat, MBBS
Samilia Obeng-Gyasi, MD, MPH,
Kian-Huat Lim, MD, PhD
Saurabh Dahiya, MD, FACP, associate professor, medicine (blood and marrow transplantation and cellular therapy), Stanford University School of Medicine, clinical director, Cancer Cell Therapy, Stanford BMT and Cell Therapy Division
Muhamed Baljevic, MD